SUN PHARM INDUSTRIES received final FDA approval on December 21 for ANDA077124, signaling a potential generic opportunity in the previously undetermined market segment. The company is positioned to capitalize on the anticipated revenue stream by leveraging this regulatory clearance to offer a cost-effective alternative.